

WEST Search History

DATE: Saturday, November 30, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
L4	L3 not l2	42	L4
L3	L1 and (ntg or gtn or nitroglycerin or (glycer\$5) near5 (nitr\$5 or trinitr\$5)) and (lanolin or wool)	57	L3
L2	L1 and (ntg or gtn or nitroglycerin or (glycer\$5) near5 (nitr\$5 or trinitr\$5)) and (lanolin or wool) and (water or h2o or h".sub."2o) and lactose	15	L2
L1	424/401 or 424/443 or 514/966 or 514/937	8895	L1

END OF SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 13:48:57 ON 30 NOV 2002)

FILE 'REGISTRY' ENTERED AT 13:49:14 ON 30 NOV 2002

L1 1 SEA NITROGLYCERIN/CN
L2 1 SEA LACTOSE/CN
L3 1 SEA LANOLIN/CN
L4 0 SEA WHITE SOFT PARAFFIN/CN
L5 1 SEA WHITE PETROLATUM/CN
D

FILE 'EMBASE, BIOSIS, EUROPATFULL, JAPIO, ADISALERTS, ADISINSIGHT, ADISNEWS, BABS, BIOBUSINESS, BIOCOMMERCE, BIOTECHNO, CANCERLIT, CAPLUS, CBNB, CEN, CIN, CONFSCI, DGENE, DIOGENES, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, DRUGUPDATES, EMBAL, ESBIOBASE, ...' ENTERED AT 13:50:34 ON 30 NOV 2002

L6 59 SEA (L1 OR NTG OR GTN OR NITROGLYCERIN) AND (L2 OR LACTOSE) AND (L3 OR LANOLIN OR WOOL (5A) (FAT OR FATS OR OIL OR OILS OR WAX OR WAXES)) AND (L4 OR WHITE SOFT PARAFFIN OR WHITE PETROLATUM OR VASELINE)

L7 57 DUP REM L6 (2 DUPLICATES REMOVED)

D 1-57
D 56 KWIC
D 55 KWIC
D 54 IALL
D 53 IALL
D 49 IALL
D 29 KWIC
D 26 IALL
D 23 IALL

L8 13 SEA L7 AND (SEXUAL OR PENILE OR PENIS OR ERECTION OR ERECTILE)

D 1-13
D 13 KWIC
D 12 KWIC

L9 11 SEA L8 AND (MAN OR MALE)

D 1-11
D 11 KWIC
D 10 KWIC

L10 22 SEA (NITROBID OR NITRO BID OR NITROSTAT OR NITRO STAT) AND (SEXUAL OR PENILE OR PENIS OR ERECTION OR ERECTILE OR AROUSAL)

L11 22 DUP REM L10 (0 DUPLICATES REMOVED)

D 1-22
D 20 IALL

FILE 'STNGUIDE' ENTERED AT 14:12:06 ON 30 NOV 2002

FILE 'EMBASE, DRUGU, PROMT, USPATFULL, HSDB, NLDB' ENTERED AT 14:13:08 ON 30 NOV 2002

D 19 IALL

FILE 'STNGUIDE' ENTERED AT 14:13:09 ON 30 NOV 2002

FILE 'EMBASE, DRUGU, PROMT, USPATFULL, HSDB, NLDB' ENTERED AT 14:14:28 ON 30 NOV 2002

D 18 IALL

FILE 'STNGUIDE' ENTERED AT 14:14:29 ON 30 NOV 2002

FILE 'EMBASE, DRUGU, PROMT, USPATFULL, HSDB, NLDB' ENTERED AT 14:15:00 ON 30 NOV 2002

D 15 IALL

FILE 'STNGUIDE' ENTERED AT 14:15:07 ON 30 NOV 2002

FILE 'EMBASE, DRUGU, PROMT, USPATFULL, HSDB, NLDB' ENTERED AT 14:16:03 ON 30 NOV 2002

D 14 IALL

FILE 'STNGUIDE' ENTERED AT 14:16:04 ON 30 NOV 2002

FILE 'EMBASE, DRUGU, PROMT, USPATFULL, HSDB, NLDB' ENTERED AT 14:16:14 ON 30 NOV 2002

D 1-14

FILE 'STNGUIDE' ENTERED AT 14:16:15 ON 30 NOV 2002

FILE 'EMBASE, DRUGU, PROMT, USPATFULL, HSDB, NLDB' ENTERED AT 14:16:33 ON 30 NOV 2002

D 13 IALL

FILE 'STNGUIDE' ENTERED AT 14:16:37 ON 30 NOV 2002

FILE 'EMBASE, DRUGU, PROMT, USPATFULL, HSDB, NLDB' ENTERED AT 14:17:48 ON 30 NOV 2002

D 7 KWIC

FILE 'STNGUIDE' ENTERED AT 14:17:52 ON 30 NOV 2002

FILE 'EMBASE, BIOSIS, EUROPATFULL, JAPIO, ADISALERTS, ADISINSIGHT, ADISNEWS, BABS, BIOBUSINESS, BIOCOMMERCE, BIOTECHNO, CANCERLIT, CAPLUS, CBNB, CEN, CIN, CONFSCI, DGENE, DIOGENES, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, DRUGUPDATES, EMBAL, ESBIOBASE, ...' ENTERED AT 14:18:53 ON 30 NOV 2002

L12 468 SEA (NTG OR GTN OR NITROGLYCERIN/CN OR NITROGLYCERIN OR (GLYCEROL OR GLYCERYL OR GLYCERINE OR GLYCERIN) (5A) (NITR? OR TRINITR?)) AND (LANOLIN OR WOOL (5A) (FAT OR FATS OR OIL OR OILS OR WAX OR WAXES)) AND (VASOLINE OR VASELINE OR LACTOSE OR PETROLATUM OR PARAFFIN OR WATER OR PARAFFIN)

L13 56 SEA L12 AND (MAN OR MALE) AND (SEX? OR ERECTILE OR PENILE OR PENIS OR AROUS? OR ERECTION)

L14 55 DUP REM L13 (1 DUPLICATE REMOVED)

D 1-55

D 52 KWIC

D 52

D 49 KWIC

D 45 KWIC

=> d his ful

(FILE 'HOME' ENTERED AT 10:52:34 ON 30 NOV 2002)

FILE 'REGISTRY' ENTERED AT 10:53:04 ON 30 NOV 2002

L1 1 SEA LANOLIN/CN
L2 1 SEA GLYCERYL TRINITRATE/CN
D
D FCN
D L1

FILE 'EMBASE, BIOSIS, EUROPATFULL, JAPIO, ADISALERTS, ADISINSIGHT, ADISNEWS, BABS, BIOBUSINESS, BIOCOMMERCE, BIOTECHNO, CANCERLIT, CAPLUS, CBNB, CEN, CIN, CONFSCI, DGENE, DIOGENES, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, DRUGUPDATES, EMBAL, ESBIOBASE, ...' ENTERED AT 10:53:53 ON 30 NOV 2002

FILE 'REGISTRY' ENTERED AT 10:54:21 ON 30 NOV 2002

L3 SET SMARTSELECT ON
SEL L2 1- CHEM : 77 TERMS
SET SMARTSELECT OFF

FILE 'EMBASE, BIOSIS, EUROPATFULL, JAPIO, ADISALERTS, ADISINSIGHT, ADISNEWS, BABS, BIOBUSINESS, BIOCOMMERCE, BIOTECHNO, CANCERLIT, CAPLUS, CBNB, CEN, CIN, CONFSCI, DGENE, DIOGENES, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, DRUGUPDATES, EMBAL, ESBIOBASE, ...' ENTERED AT 10:54:23 ON 30 NOV 2002

FILE 'REGISTRY' ENTERED AT 10:55:27 ON 30 NOV 2002

L4 SET SMARTSELECT ON
SEL L1 1- CHEM : 55 TERMS
SET SMARTSELECT OFF

FILE 'EMBASE, BIOSIS, EUROPATFULL, JAPIO, ADISALERTS, ADISINSIGHT, ADISNEWS, BABS, BIOBUSINESS, BIOCOMMERCE, BIOTECHNO, CANCERLIT, CAPLUS, CBNB, CEN, CIN, CONFSCI, DGENE, DIOGENES, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, DRUGUPDATES, EMBAL, ESBIOBASE, ...' ENTERED AT 10:55:28 ON 30 NOV 2002

L5 33478 SEA PROPANETRIOL (5A) TRINITRATE OR PROPANETRIYL (5A) NITRATE OR ANGIBID OR ANGININE OR ANGIOLIGUAL OR ANGORIN OR BLASTING OIL OR CADAMIST OR CHITAMITE OR DEPONIT OR EPINITRIL OR GILUCOR NITRO OR GLONOIN OR GLYCERIN TRINITRATE OR GLYCEROL TRINITRATE OR GLYCERYL NITRATE OR GLYCERYL TRINITRATE
L6 885970 SEA GTN OR KLAVIDAL OR LENITRAL OR MINITRAN OR MYOGLYCERIN OR NG OR NIGLIN OR NIGLIN OR NIGLYCON OR NITORA OR NITRIN OR NITRINE OR NITRO (A) (BID OR DUR OR LENT OR SPAN) OR NITROCARDI N OR NITRODERM OR NITROGLYCERINE OR NITROGLYCEROL OR NITROGLYN OR NITROL OR NITROLAN OR NITROLETEN
L7 27010 SEA NITROBID OR NITRODUR OR NITROLENT OR NITROSPAN OR NITROLING UAL OR NITROLOWE OR NITROMEL OR NITRONG OR NITROPERCUTEN OR NITRORECTAL OR NITRORETARD OR NITROSTABLIN OR NITROSTAT OR NITROZELL RETARD OR NK 843 OR NTG OR NYSCONITRINE OR PENOBEL 2 OR PERGLOTTAL OR PERLINGANIT OR SNG OR S N G
L8 2447 SEA TEMPONITRIN OR TRANSDERMNITRO OR TRANSDERM NITRO OR TRIDIL OR TRINALGON OR TRINIPLAS OR TRINITRIN OR TRINITROLGLYCERIN OR TRINITROLGLYCEROL OR TRINITROL OR VASOGLYN
L9 934893 SEA L5 OR L6 OR L7 OR L8
L10 35558 SEA LANOLIN OR ADEPS LANE OR AGNOLIN OR ALAPURIN OR LANUM OR ARGOWAX OR CLEARLAN OR COSMELAN OR CRODAPUR OR EMERY HP 2050 OR EMERY HP2050 OR WOOL (5A) (FAT OR FATS OR OIL OR OILS OR WAX OR WAXES) OR FLUILAN T OR FPG 1 OR FURUIRAN SP OR FURUIRAN T OR HHC 82 OR LANAIN OR LANALIN OR LANESIN
L11 212 SEA LANICHOL OR LANIOL OR LANOPRODINE OR LANOX OR LANTROL OR

MEDILAN OR OESIPOS OR NATRALUBE 210

L12 35598 SEA L10 OR L11
L13 1167 SEA L9 AND L12
L14 1122 DUP REM L13 (45 DUPLICATES REMOVED)
L15 274 SEA L14 AND (SEX? OR ERECTILE OR ERECTION OR PENIS OR PENILE)

L16 956846 SEA L2 OR L9
L17 35613 SEA L12 OR L1
L18 1208 SEA L16 AND L17
D L15 1-
D 258 KWIC
D 256 KWIC
D 246 KWIC
D 246 IALL ABEX
D L15 258 KWIC
D L15 257 KWIC
D 249 L15
D 249 L15 KWIC
D 233 KWIC L15
D 230 L15 KWIC
D 225 KWIC L15
D 221 KWIC L15
D 225 KWIC L15
D 215 KWIC L15
D 191 KWIC L15
D L15 191
D 162 KWIC L15
D 108 KWIC L15
D 202 KWIC L15
D 202 L15
D 38 IALL L15
D 1-37
D 1-37 L15
D 20 IALL
D 20 IALL L15

L19 8 SEA L18 AND (SEX? OR ERECTILE OR ERECTION OR PENIS OR PENILE)
NOT L15
D 1-8
D 8 KWIC
D 6 KWIC

L15 ANSWER 272 OF 274 HSDB COPYRIGHT 2002 NLM
CAS Registry No. (RN) : 55-63-0 HSDB
HSDB Number (HSN) : 30
Chemical Name (CN) : NITROGLYCERIN
Synonyms (CN) : ANGIBID **PEER REVIEWED**;
ANGININE **PEER REVIEWED**; ANGIOLINGUAL **PEER REVIEWED**;
ANGORIN **PEER REVIEWED**; BLASTING GELATIN **PEER REVIEWED**;
BLASTING OIL **PEER REVIEWED**; Cardabid **PEER
REVIEWED**; CARDAMIST **PEER REVIEWED**; (Component of) SDM No 17 **PEER
REVIEWED**; (Component of) SDM No 37 **PEER REVIEWED**; Deponit
PEER REVIEWED; GLONOIN **PEER REVIEWED**; GLYCERINTRINITRATE
(CZECH) **PEER REVIEWED**; GLYCEROLTRINITRAAT (DUTCH) **PEER REVIEWED**;
GLYCEROL TRINITRATE **PEER REVIEWED**; GLYCEROL
(TRINITRATE DE) (FRENCH) **PEER REVIEWED**; GLYCERYL
NITRATE **PEER REVIEWED**; GLYCERYL TRINITRATE
PEER REVIEWED; GTN **PEER REVIEWED**; KLAVIDKORDAL
PEER REVIEWED; LENITRAL **PEER REVIEWED**;
MYOGLYCERIN **PEER REVIEWED**; NG **PEER REVIEWED**;
NIGLYCON **PEER REVIEWED**; Niong **PEER REVIEWED**; Nitric acid
triester of glycerol **PEER REVIEWED**; NITRINE-TDC **PEER
REVIEWED**; Nitro-Bid **PEER REVIEWED**; Nitrodisc
PEER REVIEWED; Nitro-Dur **PEER REVIEWED**;
Nitrogard **PEER REVIEWED**; NITROGLICERINA (ITALIAN) **PEER REVIEWED**;
Nitroglycerina (Spanish) **PEER REVIEWED**; NITROGLICERYNA (POLISH) **PEER
REVIEWED**; NITROGLYCERINE **PEER REVIEWED**;
Nitroglycerine (French) **PEER REVIEWED**; NITROGLYCEROL
PEER REVIEWED; NITROGLYN **PEER REVIEWED**; Nitrol
PEER REVIEWED; NITROLAN **PEER REVIEWED**; NITRO-
LENT **PEER REVIEWED**; Nitrolin **PEER REVIEWED**;
NITROLINGUAL **PEER REVIEWED**; Nitrolingual Spray **PEER
REVIEWED**; NITROLOWE **PEER REVIEWED**; Nitrol
(Pharmaceutical) **PEER REVIEWED**; NITROMEL **PEER REVIEWED**;
Nitronet **PEER REVIEWED**; NITRONG **PEER REVIEWED**;
NITRORECTAL **PEER REVIEWED**; NITRORETARD **PEER
REVIEWED**; Nitrospan **PEER REVIEWED**; NITROSTAT
PEER REVIEWED; NITROZELL RETARD **PEER REVIEWED**;
NK 843 **PEER REVIEWED**; NTG **PEER
REVIEWED**; PERGLOTTAL **PEER REVIEWED**; PROPANETRIOL
TRINITRATE **PEER REVIEWED**; 1,2,3-PROPANETRIOL,
TRINITRATE **PEER REVIEWED**; 1,2,3-PROPANETRIYL
NITRATE **PEER REVIEWED**; SK-106N **PEER REVIEWED**; SOUP **PEER
REVIEWED**; Spirits of Nitroglycerin, (1 to 10%) **PEER REVIEWED**;
Susadrin **PEER REVIEWED**; Transderm-Nitro **PEER
REVIEWED**; Transderm-N TTS **PEER REVIEWED**; Tridil **PEER
REVIEWED**; TRINALGON **PEER REVIEWED**; TRINITRIN
PEER REVIEWED; Trinitrin Tablets **PEER REVIEWED**;
TRINITROGLYCERIN **PEER REVIEWED**; TRINITROGLYCEROL **PEER REVIEWED**;
VASOGLYN **PEER REVIEWED**
Shipping Name/No. (CN) : UN 0143 Nitroglycerin desensitized with not less
than 40% non-volatile water or soluble
phlegmatizer, by weight; UN 1204 Nitroglycerin
solution in alcohol with 1% or less
nitroglycerin; IMO 3.2 Nitroglycerin solution in
alcohol with 1% or less nitroglycerin; UN 0144
Nitroglycerin, spirit of with more than 1% but
not more than 10% nitroglycerin in solution in
alcohol; IMO 1.1D Nitroglycerin, spirit of with
more than 1% nitroglycerin in solution in
alcohol; Nitroglycerin, desensitized with not less
than 40% non-volatile water insoluble
phlegmatizer, by weight
STCC No. (CN) : 49 015 16 Nitroglycerin, liquid, desensitized
(high explosive liquid); 49 015 03 Blasting

gelatin (high explosive)
Last Rev. Date (RDAT) : Jul. 22, 2002
RTECS Number (RTN) : NIOSH-WG9532700
Molecular Formula (MF) : C3 H5 N3 O9 **PEER REVIEWED**
Molecular Weight (MW) : 227.09
EPA Hazard Waste No. (HZN) : P081; An acute hazardous waste when a discarded commercial chemical product or manufacturing chemical intermediate or an off-specification commercial chemical product or a manufacturing chemical intermediate.
Character Count (CHC) : 88180

Chemical Name (CN) : NITROGLYCERIN
Manufacture/Use Information

Composition (COMP) :
Nitrostat contains 0.15 mg or 0.3 mg or 0.4 mg or 0.6 mg nitroglycerin and polyethylene glycol 4000 units per tablet. **PEER REVIEWED** [Gosselin, R.E., R.P. Smith, H.C. Hodge. Clinical Toxicology of Commercial Products. 5th ed. Baltimore: Williams and Wilkins, 1984.,p. II-212]

Manufacture/Use Information

Composition (COMP) :
Nitro-Dur contains 2% w/w nitroglycerin. **PEER REVIEWED** [Gosselin, R.E., R.P. Smith, H.C. Hodge. Clinical Toxicology of Commercial Products. 5th ed. Baltimore: Williams and Wilkins, 1984.,p. II-212]

Manufacture/Use Information

Composition (COMP) :
Nitroglyn contains 1/10, 1/25 or 1/50 gr nitroglycerin per tablet. **PEER REVIEWED** [Gosselin, R.E., R.P. Smith, H.C. Hodge. Clinical Toxicology of Commercial Products. 5th ed. Baltimore: Williams and Wilkins, 1984.,p. II-212]

Manufacture/Use Information

Composition (COMP) :
Nitrol ointment contains 2% nitroglycerin in a **lanolin**-petroleum base. **PEER REVIEWED** [Gosselin, R.E., R.P. Smith, H.C. Hodge. Clinical Toxicology of Commercial Products. 5th ed. Baltimore: Williams and Wilkins, 1984.,p. II-212]

Manufacture/Use Information

Composition (COMP) :
/Nitrostat & Nitro-Bid/ ointment contains 2% nitroglycerin in a base composed of **lanolin**, lactose, and white petroleum. **PEER REVIEWED** [Physicians Desk Reference p.1176 (1987)]

Manufacture/Use Information

Composition (COMP) :
/Nitro-Bid IV/ each milliliter contains 5 mg nitroglycerin and 45 mg propylene glycol dissolved in 70% ethanol. **PEER REVIEWED** [Physicians Desk Reference p.1176 (1987)]

Manufacture/Use Information

Composition (COMP) :
Transderm-Nitro transdermal therapeutic system is a flat unit ... rated to release in vivo 2.5, 5, 10, and 15 mg nitroglycerin

over 24 hr and sizes of 5, 10, 20, and 30 cm sq, respectively. **PEER REVIEWED** [Physicians Desk Reference p.864 (1987)]

Manufacture/Use Information

Composition (COMP):

Each ml of Tridil 5 mg contains 0.5 mg nitroglycerin 4.5 mg lactose, USP, 10% alcohol, USP, 30% propylene glycol, USP, and water for injection, USP. **PEER REVIEWED** [Physicians Desk Reference p.595 (1987)]

Pharmacology

Therapeutic Uses (THER):

PATIENTS RECEIVED 0.3 MG OF GLYCERYL NITRATE 1-4 TIMES/DAY SUBLINGUALLY FOR TREATMENT OF CHEST PAIN. 2 DAYS LATER PATIENTS EXPERIENCED 1ST ERECTION IN 2.5 YR LASTING 10 MIN & REOCCURRED 3-4 TIMES/WK. SUGGESTS VASODILATORY EFFECT. **QC REVIEWED** [MUDD JW; AM J PSYCHIATRY 134 (AUG): 922-5 (1977)]

Environmental Impact

Probable Routes of Human Exposure (RTEX):

12,335 workers are potentially exposed to nitroglycerin based on statistical estimates derived from the NIOSH survey conducted in 1972-1974 in the USA. (1). This survey sampled 5000 business in 67 metropolitan areas throughout the USA for the manufacture and use of chemicals, grade name products known to contain the compound and generic products suspected of containing the compound. 1,266 workers are potentially exposed to nitroglycerin based on statistical estimates derived from the NIOSH survey conducted in 1981-1983 in the USA(2). Glycerol trinitrate (GTN) adsorption was determined in 12 subjects working in a gun factory. Blood was collected from the cubital vein of seven males and five females before and during work at the mill roll and press site production areas and after a sublingual dose of GTN. Control samples were drawn from the femoral vein. The concentration of GTN in the cubital vein increased significantly during work at both sites. Control blood from the femoral vein contained much less GTN, indicating that the GTN in the cubital vein was enriched by dermal absorptions. For each individual, the plasma concentration was higher in the roll mill area than in the press area with some workers at each site showing consistently higher values(3). Since the NOES survey excludes exposure to trade name products which may contain the chemical, occupational exposure should be considerably higher(SRC). **PEER REVIEWED** [(1) NIOSH; National Occupational Health Survey (1975) (2) NIOSH; National Occupational Exposure Survey (1985) (2) Gjesdal K etal; Brit J Industr Med 42: 27-31 (1985)]

Monitoring and Analysis Methods

Analytic Laboratory Method (ALAB):

Glycerol trinitrate traces (4-5 pg level) were detected at high sensitivity using the thermal energy analyzer coupled with gas chromatography or high performance liquid chromatography. Analyses of explosives, postblast debris, postblast air samples, and handswab experiments ... are described. **PEER REVIEWED** [Fine DH, Yu WC; J Forensic Sci 29 (3): 732-46 (1984)]

Monitoring and Analysis Methods

Analytic Laboratory Method (ALAB):

Nitroglycerin and isosorbide dinitrate were detected in tablets by chromatography on a RP-18 column with methyl alcohol (MeOH)-H₂O (1:1) or methyl cyanide (MeCN)-H₂O (3:2) by using detection at 220 nm.

Chromatography on an Aminosil column allowed elution with H₂O and detection at 210 nm with greater sensitivity in the range of 50-700 ng. The relative standard deviation was 2.1% for nitroglycerin and 2.7% for isosorbide dinitrate. Requirements for content uniformity vary for nitroglycerin tablets depending on release rate (sustained gastrointestinal release, sublingual sustained, or sublingual immediate release). **PEER REVIEWED** [Torok I, Paal T; Acta Pharm Hung 55 (5): 154-62 (1985)]

Monitoring and Analysis Methods

Clinical Laboratory Method (CLAB):

Glycerol trinitrate ... traces (4-5 pg level) were detected at high sensitivity using the thermal energy analyzer coupled with gas chromatography or high performance liquid chromatography. Analyses of ... human blood /samples/ are described. **PEER REVIEWED** [Fine DH, Yu WC; J Forensic Sci 29 (3): 732-46 (1984)])

Monitoring and Analysis Methods

Clinical Laboratory Method (CLAB):

A new, sensitive, and specific high performance liquid chromatography method for the quantitative analysis of glyceryl trinitrate and its 4 metabolites (1,2-glyceryldinitrate, 1,3-glyceryldinitrate, 1-glyceryl mononitrate, and 2-glyceryl mononitrate in plasma is described. A 0.01 ml solution of silver nitrate was added to 0.05 ml of rat plasma sample and extracted 3 times with methanol. The organic layer was collected and condensed to 0.1 ml. Ten to 30 microliters of the solution were subjected to high performance liquid chromatography analyses. Analysis was by high performance liquid chromatography using a synchronized accumulating radioisotope detector. The limit of detection is 0.2 ng/injection. Absolute recovery of GTN from plasma was 86.5. The within day coefficient of variation is 5.9% at a concn of 27.0 ng/ml of plasma. The method was applied to single dose pharmacokinetics of glyceryl trinitrate in rat.

PEER REVIEWED [Baba S et al; J Chromatogr 305 (1): 119-26 (1984)]

L15 ANSWER 273 OF 274 HSDB COPYRIGHT 2002 NLM
CAS Registry No. (RN) : 52-24-4 HSDB
HSDB Number (HSN) : 3258
Chemical Name (CN) : THIO-TEPA
Last Rev. Date (RDAT) : May 31, 2002
RTECS Number (RTN) : NIOSH-SZ2975000
Molecular Formula (MF) : C₆ H₁₂ N₃ P S **PEER REVIEWED**
Molecular Weight (MW) : 189.23
Character Count (CHC) : 73448

Toxicity

Non-Human Toxicity Excerpt (NTXE):

Thiota induced dominant lethal mutations, chromosomal aberrations, micronuclei and sister chromatid exchanges in rodents treated in vivo. It induced sister chromatid exchanges & chromosomal aberrations in human and rodent cells in vitro and transformation of C3H 10T1/2 mouse cells. It was mutagenic to Chinese hamster cells in vitro & to mouse lymphoma cells in a host-mediated assay. Thiota induced sex-linked recessive lethal mutations in Drosophila, caused sister chromatid exchanges and chromosomal aberrations in plant cells and was mutagenic to fungi and to bacteria in vitro & in host-mediated assays. **PEER REVIEWED** [IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work), p. S6 549 (1987)]

L18 ANSWER 246 OF 1208 DRUGU COPYRIGHT 2002 THOMSON DERWENT
ACCESSION NUMBER: 1984-36413 DRUGU G
TITLE: Study of In Vitro Release of Nitroglycerin From Percutaneous Formulations. Part. I.
AUTHOR: Pirotte B; Jaminet F
LOCATION: Liege, France
SOURCE: J.Pharm.Belg. (39, No. 1, 23-35, 1984) 10 Fig. 2 Tab. 19 Ref.
CODEN: JPBEAJ ISSN: 0047-2166
AVAIL. OF DOC.: Universite de Liege, Institut de Pharmacie, Service de Pharmacie Galenique, Belgium.
LANGUAGE: French
DOCUMENT TYPE: Journal

ABSTRACT:

Release of nitroglycerin (NG) from an ointment containing vaseline and lanolin as excipients (Lenitral, Besins-Iscovesco), was affected by temperature and concentration of active drug in the ointment.

SECTION HEADING: G Galenics

CLASSIF. CODE: 9 Cardiovascular
29 Pharmaceutics

CONTROLLED TERM:

OINTMENT *FT; TEMPERATURE *FT; PHARM.PREP. *FT
[01] NITROGLYCEROL *OC; LENITRAL *OC;
BESINS-ISCOVESCO *FT; DIFFUSION *FT; RELEASE *FT; RATE *FT;
KINETICS *FT; CARDIANTS *FT; SPASMOlyTICS *FT;
CALCIUM-ANTAGONISTS *FT; NITROGLYC *RN; OC *FT
[02] PETROLATUM *OC; AUXILIARY-INGREDIENT *FT; PHARMACEUTICS *FT;
PETROLATU *RN; OC *FT
[03] LANOLIN *OC; AUXILIARY-INGREDIENT *FT;
PHARMACEUTICS *FT; LANOLIN *RN; OC *FT

FIELD AVAIL.: AB; LA; CT; MPC

FILE SEGMENT: Literature

ABEX Diffusion of NG from a commercial ointment containing 2% NG and vaseline and lanolin as excipients was measured using an in vitro method without membrane located between the test product and dissolution medium. NG was determined spectrophotometrically. Release of NG followed 1st order characteristics. An increase in temperature and in concentration of NG in the ointment (0.5-4% w/w), resulted in an increased release rate. The quantity of ointment per unit contact area with the dissolution medium had almost no effect on NG release rate.
(Etude De La Liberation In Vitro De La Nitroglycerine A Partir De Formulations Galeniques Destinees A La Voie Percutanee. Partie I.)

L14 ANSWER 52 OF 55 USPATFULL
AN 88:32746 USPATFULL
TI External pharmaceutical composition
IN Makino, Yuji, Hino, Japan
Suzuki, Yoshiki, Hino, Japan
PA Teijin Limited, Osaka, Japan (non-U.S. corporation)
PI US 4746675 19880524
AI US 1986-924189 19861027 (6)
RLI Continuation of Ser. No. US 1984-595835, filed on 2 Apr 1984, now
abandoned
PRAI JP 1983-57908 19830404
DT Utility
FS Granted
LN.CNT 1374
INCL INCLM: 514/423.000
INCLS: 514/946.000; 514/947.000
NCL NCLM: 514/423.000
NCLS: 514/946.000; 514/947.000
IC [4]
ICM: A61K031-40
EXF 514/423; 514/946; 514/947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:446300 CAPLUS
DOCUMENT NUMBER: 107:46300
TITLE: Topical pharmaceuticals containing
nitroglycerin for the treatment of skin
disorders
INVENTOR(S): Kurono, Masatsune; Yamazaki, Taisuke; Inukai, Tsutomu
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
INT. PATENT CLASSIF.:
MAIN: A61K031-21
SECONDARY: A61K009-06; A61K009-10; A61K009-18; A61K031-21
ADDITIONAL: C07C077-04
CLASSIFICATION: 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61286327	A2	19861216	JP 1985-126425	19850612
JP 06065647	B4	19940824		

ABSTRACT:

A topical pharmaceutical contains a small amt. of nitroglycerin for accelerating peripheral blood circulation and skin respiration. Thus, an ointment was prep'd. consisting of nitroglycerin 10, lactose 90, 25% H2O-contg. lanolin 600, and white Vaseline to 1000 g. The efficacy for treating frostbite in rats was demonstrated.

SUPPL. TERM: nitroglycerin pharmaceutical skin disorder
INDEX TERM: Skin, disease or disorder
(treatment of, nitroglycerin pharmaceuticals
for)
INDEX TERM: 55-63-0, Nitroglycerin
ROLE: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(pharmaceuticals contg., for skin disorder treatment)

=>

L27 ANSWER 28 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.DUPLICATE 2
ACCESSION NUMBER: 90112436 EMBASE
DOCUMENT NUMBER: 1990112436
TITLE: Topical glyceryltrinitrate causes measurable
penile arterial dilation in
impotent men.
AUTHOR: Heaton J.P.W.; Morales A.; Owen J.; Saunders F.W.; Fenemore
J.
CORPORATE SOURCE: Department of Urology, Queen's University, Kingston, Ont.,
Canada
SOURCE: Journal of Urology, (1990) 143/4 (729-731).
ISSN: 0022-5347 CODEN: JOURAA
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 028 Urology and Nephrology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:
The current understanding of the intracavernous changes that cause or accompany
penile erections has encouraged the use of vasodilators as therapy for
erectile dysfunction. An established vasodilator, glyceryltrinitrate, was
selected for in vivo study because of its rapid transdermal absorption. Color
coded duplex ultrasound was used to assess penile vascular response.
In a large group of men with erectile dysfunction significant
dilation was noted in response to a small amount of nitroglycerine paste
applied to the penis. There is a measurable vasodilatory response that can be
induced by synthetic nitrates in penile tissue in impotent
men .
CONTROLLED TERM: Medical Descriptors:
*impotence: DT, drug therapy
*vasodilatation
echography
major clinical study
human
male
topical drug administration
article
priority journal
Drug Descriptors:
*glyceryl trinitrate: PD, pharmacology
*glyceryl trinitrate: DT, drug therapy
CAS REGISTRY NO.: (glyceryl trinitrate) 55-63-0

=>

2 ANSWER 4 OF 6 DRUGU COPYRIGHT 2002 THOMSON DERWENT

ACCESSION NUMBER: 1993-47896 DRUGU T S

TITLE: **Nitroglycerin Ointment in the Treatment of Impotence.**

AUTHOR: Nunez B D; Anderson D C Jr

LOCATION: Boston, Massachusetts, Oklahoma City, Oklahoma, United States

SOURCE: J.Urol. (150, No. 4, 1241-43, 1993) 46 Ref.

CODEN: JOURAA ISSN: 0022-5347

AVAIL. OF DOC.: Section of Pharmacy Practice, College of Pharmacy, University of Oklahoma Health Sciences Center, P.O. Box 26901, Oklahoma City, Oklahoma 73190-5040, U.S.A. (D.C.A.Jr).

LANGUAGE: English

DOCUMENT TYPE: Journal

ABSTRACT:

The cases are reported of 3 patients where topical nitroglycerin ointment (NG) was successfully used in the treatment of impotence. 2 Patients had hypertension treated with captopril and hydrochlorothiazide and by salt restriction, respectively, and all patients had extensive pelvic arteriosclerosis. A latex condom was used. Adjusting the antihypertensive medications had no effect on the impotence. 2 Patients had minor side-effects (1 episode of frontal headache in 1 patient). There were no signs of contact dermatitis or complaints from sexual partners. It is concluded that topical NG is potentially useful in impotence secondary to vascular insufficiency. Placebo-controlled double-blind trials of nitrates under normal sexual conditions are needed.

SECTION HEADING: T Therapeutics
S Adverse Effects

CLASSIF. CODE: 35 Adverse Reactions
58 Vasoactive

CONTROLLED TERM:

[01] NITROGLYCEROL *TR; NITROGLYCEROL *AE; IMPOTENCE *TR;
VASCULAR-DISEASE *TR; ARTERIOSCLEROSIS *OC; HEADACHE *AE;
VASCULAR-DISEASE *OC; CAPTOPRIL *RC; HYDROCHLOROTHIAZIDE *RC;
NITROGLYC *RN; IN-VIVO *FT; CASE-HISTORY *FT; TOPICAL *FT;
OINTMENT *FT; VASODILATOR *FT; CASES *FT; PHARM.PREP. *FT;
CARDIANTS *FT; SPASMODYLYTICS *FT; CALCIUM-ANTAGONISTS *FT; TR
*FT; AE *FT

CAS REGISTRY NO.: 55-63-0

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

ABEX In a 55-yr-old man with a 6-mth history of hypertension and lower back pain, pain and numbness in the lower extremities after walking was accompanied by impotence and loss of morning erection. B.P. had been controlled with captopril and hydrochlorothiazide; adjustment of these drugs had no effect on impotence. An aortogram showed severe widespread arteriosclerosis. The patient's main concern was his impotence. He was instructed to apply 1.5 inches of 2% NG ointment to the shaft of the penis when he wanted an erection, to use a latex condom during intercourse and to wash the penis immediately after intercourse. The patient reported a complete erection, normal sexual intercourse and ejaculation after NG, a return of morning erections and an entire wk of success with the treatment. There were no signs of allergic dermatitis or tolerance to the effects of NG. There were no side effects, apart from 1 episode of mild frontal headache. A 56-yr-old man with borderline hypertension (controlled by salt restriction), obesity and severe arteriosclerosis was instructed to use NG ointment for impotence. At 6 mth follow up he reported complete success of NG therapy. There was no contact dermatitis. A 62-yr-old man with intermittent claudication and moderate to severe arteriosclerosis instructed to use NG

ointment for impotence had good erectile function at 6 mth. Side-effects were minor. (E8/YC)

=>


ACCESSION NUMBER: 93:8387 IPA
DOCUMENT NUMBER: 31-03182
TITLE: **Topical nitrate treatment of impotence**
AUTHOR: Anderson, D. C.; Seifert, C. F.
CORPORATE SOURCE: Sec. of Pharm. Practice, Coll. of Pharm., Univ. of Oklahoma Hlth. Sci. Ctr., P.O. Box 26901, Oklahoma City, OK 73190, USA
SOURCE: Annals of Pharmacotherapy, (Oct 1993) Vol. 27, pp. 1203-1205. 17 Refs.
CODEN: APHRER.
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:
The use of topical nitroglycerin for the treatment of impotence is discussed, including effects of nitroglycerin on human penile smooth muscle tissue and an overview of clinical studies designed to assess the efficacy of various topical nitroglycerin formulations, such as ointments, patches, and sustained-release adhesive plasters, in the treatment of impotence.
M. Therese Gyi
SECTION: 11 Pharmacology; 6 Drug Evaluations
CLASSIFICATION: 24:12 Vasodilating agents; 84:00 Topical preparations; 84:24 Ointments
INDEX TERM: Nitroglycerin; impotence; topical therapy, overview
INDEX TERM: Vasodilating agents; nitroglycerin; topical therapy, impotence, overview
INDEX TERM: Topical preparations; nitroglycerin; impotence therapy, overview
INDEX TERM: Plasters; nitroglycerin; sustained-release, topical therapy, impotence
INDEX TERM: Impotence; nitroglycerin; topical therapy, overview
INDEX TERM: Sustained-action medications; nitroglycerin; plasters, impotence therapy, overview
INDEX TERM: Ointments; nitroglycerin; impotence therapy, overview
INDEX TERM: Patches transdermal; nitroglycerin; impotence therapy, overview
INDEX TERM: Clinical studies; nitroglycerin; topical therapy, impotence, overview
INDEX TERM: Dosage forms; nitroglycerin; topical therapy, impotence, overview
CAS REGISTRY NO.: 55-63-0 (Nitroglycerin)

CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5993 REFERENCES IN FILE CA (1962 TO DATE)

30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

6002 REFERENCES IN FILE CAPLUS (1962 TO DATE)

7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d fcn

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
CN 1,2,3-Propanetriol, trinitrate (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Nitroglycerin (8CI)

OTHER NAMES:

CN 1,2,3-Propanetriyl nitrate

CN Angibid

CN Anginine

CN Angiolingual

CN Angorin

CN Blasting oil

CN Cardamist

CN Chitamite

CN Deponit

CN Epinitril

CN Gilucor nitro

CN Glonoin

CN Glycerin trinitrate

CN Glycerol trinitrate

CN Glyceryl nitrate

CN Glyceryl trinitrate

CN GTN

CN Klavikordal

CN Lenitral

CN Minitran

CN Minitran (nitroglycerin)

CN Myoglycerin

CN NG

CN Niglin

CN Niglycon

CN Nitora

CN Nitrin

CN Nitrine

CN Nitrine-TDC

CN Nitro-Bid

CN Nitro-Dur

CN Nitro-lent

CN Nitro-Span

CN Nitrocardin
CN Nitroderm
CN Nitroglycerine
CN Nitroglycerol
CN Nitroglyn
CN Nitrol
CN Nitrol (pharmaceutical)
CN Nitrolan
CN Nitroletten
CN Nitrolingual
CN Nitrolowe
CN Nitromel
CN Nitrong
CN Nitropercuten
CN Nitrorectal
CN Nitroretard
CN Nitrostabilin
CN Nitrostat
CN Nitrozell retard
CN NK 843
CN NTG
CN Nysconitrine
CN Penobel 2
CN Perglottal
CN Perlinganit
CN Propanetriol trinitrate
CN S.N.G.
CN Soup
CN Temponitrin
CN Transderm-Nitro
CN Tridil
CN Trinalgon
CN Triniplas
CN Trinitrin
CN Trinitroglycerin
CN Trinitroglycerol
CN Trinitrol
CN Vasoglyn

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 8006-54-0 REGISTRY *
* Use of this CAS Registry Number alone as a search term in other STN files may
result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).
CN Lanolin (CA INDEX NAME)

OTHER NAMES:

CN Adeps lane
CN Agnolin
CN Agnolin No. 1
CN Alapurin
CN Amber lanolin
CN Anhydrous lanolin
CN Anhydrous Lanum
CN Argowax
CN Clearlan
CN Clearlan 1650
CN Coronet
CN Cosmelan
CN Crodapur
CN Emery HP 2050
CN Fats and Glyceridic oils, lanolin

CN Fats and Glyceridic oils, wool
CN Fats, lanolin
CN Fats, wool
CN Fluilan T
CN FPG 1
CN Furuiran SP
CN Furuiran T
CN HHC 82
CN Lanain
CN Lanalin
CN Lanesin
CN Lanichol
CN Laniol
CN Lanoprodine
CN Lanox CNB 50
CN Lanox CNB 500
CN Lanox CNB 80
CN Lanox FP 1410N
CN Lanox FP 8
CN Lanox FP 85N
CN Lanox FPG 103
CN Lanox FPG 105
CN Lanox FPK 108
CN Lanox HH 73
CN Lanox HHC 82
CN Lantrol
CN Lanum
CN Medilan
CN Natralube 210
CN Oesipos
CN Processed lanolin
CN Super Lanolin
CN Wool wax, lanolin
DEF Fat-like substance derived from sheep wool. Contains a complex combination of esters and polyesters, consisting chiefly of cholesteryl and isoocholesteryl esters of the higher fatty acids.
DR 8036-05-3, 8038-41-3, 8038-43-5, 8040-96-8, 114471-15-7
MF Unspecified
CI COM, MAN, CTS
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA,
CANCERLIT, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, DETHERM*, DIOGENES,
EMBASE, HSDB*, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PDLCOM*, RTECS*,
TOXCENTER, TULSA, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
5 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 55-63-0 REGISTRY
CN 1,2,3-Propanetriol, trinitrate (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nitroglycerin (8CI)
OTHER NAMES:
CN 1,2,3-Propanetriyl nitrate
CN Angibid
CN Anginine
CN Angiolingual
CN Angorin
CN Blasting oil
CN Cardamist
CN Chitamite
CN Deponit
CN Epinitril
CN Gilucor nitro
CN Glonoin
CN Glycerin trinitrate
CN Glycerol trinitrate
CN Glyceryl nitrate
CN Glyceryl trinitrate
CN GTN
CN Klavikordal
CN Lenitral
CN Minitran
CN Minitran (nitroglycerin)
CN Myoglycerin
CN NG
CN Niglin
CN Niglycon
CN Nitora
CN Nitrin
CN Nitrine
CN Nitrine-TDC
CN Nitro-Bid
CN Nitro-Dur
CN Nitro-lent
CN Nitro-Span
CN Nitrocardin
CN Nitroderm
CN Nitroglycerine
CN Nitroglycerol
CN Nitroglyn
CN Nitrol
CN Nitrol (pharmaceutical)
CN Nitrolan
CN Nitroletten
CN Nitrolingual
CN Nitrolowe
CN Nitromel
CN Nitrong
CN Nitropercuten
CN Nitrorectal
CN Nitroretard
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY
FS 3D CONCORD
DR 8013-23-8, 9010-02-0, 105469-31-6, 80066-48-4
MF C3 H5 N3 O9
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,

L27 ANSWER 29 OF 29 DRUGU COPYRIGHT 2002 THOMSON DERWENT
ACCESSION NUMBER: 1989-15827 DRUGU T S
TITLE: **Topical Nitroglycerin: A Potential Treatment for Impotence.**
AUTHOR: Owen J A; Saunders F; Harris C; Fenemore J; Reid K; Surridge D
LOCATION: Ontario, Canada
SOURCE: J.Urol. (141, No. 3, 546-48, 1989) 1 Tab. 17 Ref.
CODEN: JOURAA ISSN: 0022-5347
AVAIL. OF DOC.: Psychopharmacology Laboratory, Kingston Psychiatric Hospital, Kingston, Ontario, K7L 4X3, Canada. (8 authors).
LANGUAGE: English
DOCUMENT TYPE: Journal

ABSTRACT:

In a double-blind, placebo-controlled, crossover study under laboratory conditions, nitroglycerin (MTG; Rorer) paste was superior to placebo ointment for the incidence and degree of increased penile circumference in 26 **impotent men**, following local application and erotic visual stimulation. In the absence of erotic stimulation, duplex ultrasonography showed a NTG-induced increase in cavernous artery diameter and blood flow. Localization of NTG activity was indicated by increased tumescence and rarity of side effects (hypotension and headache in 1 patient).

SECTION HEADING: T Therapeutics
S Adverse Effects

CLASSIF. CODE: 15 Drugs in Fertility
35 Adverse Reactions
58 Vasoactive
64 Clinical Trials

CONTROLLED TERM:

[01] NITROGLYCEROL *TR; NITROGLYCEROL *AE; RORER *FT; IMPOTENCE *TR; HYPOTENSION *AE; VASCULAR-DISEASE *AE; HEADACHE *AE; TOPICAL *FT; IN-VIVO *FT; DOUBLE *FT; BLIND-TEST *FT; CLIN.TRIAL *FT; PLACEBO *FT; ERECTION *FT; CASES *FT; VASODILATOR *FT; PENIS *FT; CARDIANTS *FT; SPASMOLYTICS *FT; CALCIUM-ANTAGONISTS *FT; NITROGLYC *RN; TR *FT; AE *FT

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

ABEX Methods On 2 consecutive mornings, following overnight assessment of nocturnal penile tumescence, a half-inch of 2% NTG paste and placebo ointment (in random order) was applied to the penile shaft of 26 **men** (average age 53 yr) with a history of organic (12 patients), psychogenic (6 patients), or mixed organic/psychogenic (8 patients) impotence for at least 3 mth. Erectile responses to a 5-min video of explicit heterosexual activity were then examined. Results Penile circumference (measured by calibrated strain gauge transducer) increased over baseline value by an average 7.35 mm in 22/26 subjects with placebo ointment, and by 9.21 mm in 25 subjects with NTG. NTG induced an average tumescence of 36% of maximum penile circumference (measured by the corporeal calibration test in 16 **men**). The erectile response to NTG averaged 36% less than the maximal response during nocturnal assessment (56% of maximum), and exceeded the nocturnal value in 3. Ultrasonography, before and after application of NTG showed a NTG-induced increase in arterial diameter and blood flow (by 50% and over) in 7/20 patients studied. 3 Patients showed increased tumescence. Side effects in 1 patients was hypotension and headache. (S64/SP)

L11 ANSWER 19 OF 22 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 87084171 EMBASE
DOCUMENT NUMBER: 1987084171
TITLE: Pharmacocarteriography in the evaluation of impotence.
AUTHOR: Bookstein J.J.; Valji K.; Parsons L.; Kessler W.
CORPORATE SOURCE: Department of Radiology, University of California San
Diego, San Diego, CA 92103-9981, United States
SOURCE: Journal of Urology, (1987) 137/2 (333-337).
CODEN: JOURAA
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
028 Urology and Nephrology
014 Radiology
LANGUAGE: English
ABSTRACT:
Progress in diagnosis and therapy of impotence is handicapped by the absence of a validated and objective method for evaluating the vascular system; a gold-standard for vasculogenic impotence is needed. Prior experience has indicated that conventional arteriography in unanesthetized patients is unreliable in evaluation of the **penile** arterial supply. We have improved our arteriographic methods by the routine application of selective pudendal injections, vasodilation pharmacoangiography with nitroglycerin and papaverine, and direct magnification. Experience in 37 impotent patients demonstrates marked improvement in the quality of visualization of distal vessels, and the frequent presence of functional vasoconstriction of medium and small arteries that can be distinguished from organic disease only with vasodilators. We believe these angiographic methods will improve the criteria against which other diagnostic and therapeutic methods can be objectively assessed.
CONTROLLED TERM: Medical Descriptors:
*impotence
*penis artery
*pharmacocangiography
*drug therapy
arteriography
diagnosis
male genital system
priority journal
therapy
intraarterial drug administration
clinical article
human
peripheral vascular system
Drug Descriptors:
*glyceryl trinitrate
*papaverine
*acetylcholine
*phentolamine
*tolazoline
CAS REGISTRY NO.: (glyceryl trinitrate) 55-63-0; (papaverine) 58-74-2,
61-25-6; (acetylcholine) 51-84-3, 60-31-1, 66-23-9;
(phentolamine) 50-60-2, 73-05-2; (tolazoline) 59-97-2,
59-98-3
CHEMICAL NAME: Nitrobid

=>

L1 ANSWER 5 OF 6 SCISEARCH COPYRIGHT 2002 ISI (R)
 ACCESSION NUMBER: 92:49289 SCISEARCH
 THE GENUINE ARTICLE: GY923
 TITLE: **NONINVASIVE MANAGEMENT OF
IMPOTENCE WITH TRANSCUTANEOUS
NITROGLYCERIN**
 AUTHOR: MEYHOFF H H (Reprint); ROSENKILDE P; BODKER A
 CORPORATE SOURCE: UNIV COPENHAGEN, GLOSTRUP HOSP, DEPT UROL, DK-2600
 GLOSTRUP, DENMARK
 COUNTRY OF AUTHOR: DENMARK
 SOURCE: BRITISH JOURNAL OF UROLOGY, (JAN 1992) Vol. 69, No. 1, pp.
 88-90.
 ISSN: 0007-1331.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: CLIN
 LANGUAGE: ENGLISH
 REFERENCE COUNT: 10
 ABSTRACT:

Nitroglycerin plasters were applied to the penis in 10 impotent men and the erectile effect assessed. During laboratory testing all patients achieved an erectile response. Self-administration of **nitroglycerin** patches restored potency in 4 patients and was preferred to papaverine auto-injection by 3. Headache was a common side effect during initial administration. An attempt to treat **impotence** with *****nitroglycerin***** plaster seems worthwhile before starting extensive investigations or invasive treatment.

CATEGORY: UROLOGY & NEPHROLOGY
 SUPPL. TERM PLUS: MEN
 REFERENCE(S):

Referenced Author (RAU)	Year (R PY)	VOL (R VL)	PG (R PG)	Referenced Work (RWK)
BOOKSTEIN J J	1987	137	333	J UROLOGY
CLAES H	1989	44	309	UROL INT
HEATON J P W	1989	67	78	CAN J PHYSIOL PHARM
HEATON J P W	1990	143	729	J UROLOGY
MUDD J W	1977	134	922	AM J PSYCHIAT
NEGELEV S	1990	143	586	J UROLOGY
OWEN J A	1989	141	546	J UROLOGY
RIESS W	1985		9	TRANSDERMAL NITROGLY
TALLEY J D	1985	103	804	ANN INTERN MED
WAGENKNECHT L V	1989	16	262	EUR UROL

=> d 6 iall

L1 ANSWER 6 OF 6 TOXCENTER COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:24602 TOXCENTER
 DOCUMENT NUMBER: 92145340 PubMed ID: 1737261
 TITLE: **Non-invasive management of
impotence with transcutaneous
nitroglycerin**
 AUTHOR(S): Meyhoff H H; Rosenkilde P; Bodker A
 CORPORATE SOURCE: Department of Urology, Glostrup Hospital, University of Copenhagen, Denmark
 SOURCE: BRITISH JOURNAL OF UROLOGY, (1992 Jan) 69 (1) 88-90.
 Journal Code: 15740090R. ISSN: 0007-1331.
 COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 FILE SEGMENT: MEDLINE
 OTHER SOURCE: MEDLINE 92145340
 LANGUAGE: English
 ENTRY DATE: Entered STN: 20011116

Last Updated on STN: 20011116

ABSTRACT:

Nitroglycerin plasters were applied to the penis in 10 impotent men and the erectile effect assessed. During laboratory testing all patients achieved an erectile response. Self-administration of nitroglycerin patches restored potency in 4 patients and was preferred to papaverine auto-injection by 3. Headache was a common side effect during initial administration. An attempt to treat **impotence** with ***nitroglycerin*** plaster seems worthwhile before starting extensive investigations or invasive treatment.

CONTROLLED TERM: Check Tags: Human; Male

Administration, Cutaneous

Aged

Headache: CI, chemically induced

***Impotence**: DT, drug therapy

Middle Age

***Nitroglycerin**: AD, administration & dosage

Nitroglycerin: AE, adverse effects

Nitroglycerin: TU, therapeutic use

Penile Erection: DE, drug effects

REGISTRY NUMBER: 55-63-0 (**Nitroglycerin**)

L7 ANSWER 23 OF 57 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:144728 CAPLUS
DOCUMENT NUMBER: 132:185457
TITLE: Pharmaceuticals containing glyceryl trinitrate and lanolin for inorgasmia treatment
INVENTOR(S): Kemp, Colin Anthony
PATENT ASSIGNEE(S): Futura Medical Limited, UK
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
INT. PATENT CLASSIF.:
 MAIN: A61K031-21
 SECONDARY: A61K047-44; A61P013-10; A61P015-00
CLASSIFICATION: 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010559	A1	20000302	WO 1999-GB2791	19990824
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9955243	A1	20000314	AU 1999-55243	19990824
PRIORITY APPLN. INFO.:			GB 1998-18524	A 19980825
			WO 1999-GB2791	W 19990824

ABSTRACT:

A compn. and method for the treatment of female inorgasmia and for prevention of bacterial infection of the bladder during sexual intercourse involves the use of glyceryl trinitrate and lanolin in combination. Thus, a compn. contained glyceryl trinitrate 10, lanolin 44, white ***soft*** paraffin 21, and demineralized water 25% by wt. A gel formulation contg. 0.75% by wt. glyceryl trinitrate was tested on 19 patients who had reported at least a 2-yr period without organism. The formulation had a pos. effect on women.

SUPPL. TERM: lanolin glyceryl trinitrate inorgasmia; orgasm
lanolin glyceryl trinitrate
INDEX TERM: Drug delivery systems
(gels, topical; pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)
INDEX TERM: Bladder
(infection; pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)
INDEX TERM: Sexual behavior
(orgasm, disorder; pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)
INDEX TERM: Skin
(pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)
INDEX TERM: Lanolin
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

INDEX TERM: (pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)

INDEX TERM: Drug delivery systems
(unit dosage forms; pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)

INDEX TERM: 55-63-0, Glyceryl trinitrate
ROLE: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)

INDEX TERM: 63-42-3, Lactose
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals contg. glyceryl trinitrate and lanolin for inorgasmia treatment)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S) : (1) Allen Michael, P; WO 9627372 A 1996 CAPLUS
(2) Ding; British Journal of Urology 1993, V72(6), P986 MEDLINE
(3) House, D; Today's Therapeutic Trends 1984, V2(1), P7
(4) Vivus Inc; WO 9921562 A 1999 CAPLUS

ACCESSION NUMBER: 83:20072 PROMT

TITLE: Warner-Lambert's Parke-Davis Div has introduced Nitrostat ointment for treatment of acute angina attacks.

SOURCE: Chemical Marketing Reporter, (10 Jan 1983) pp. 51.

LANGUAGE: English

ABSTRACT:

Nitrostat contains 2 percent nitroglycerin in a base of ***lanolin***, lactose and white petrolatum and provides up to 8 hours of relief.

PRODUCT CODE: *PC2834300 Cardiovascular Preparations

EVENT CODE: *EC33 Product Design & Development

CORPORATE NAME: *Parke-Davis

GEOGRAPHIC TERM: New: *CC1USA United States

Old: *CC1USA United States

FEATURES: COMPANY

CAS REGISTRY NO.: 55-63-0 (NITROGLYCERIN)

55-63-0 (NITROSTAT)

63-42-3Q, 37383-89-4Q (LACTOSE)